Featured Research

from universities, journals, and other organizations

When It Comes To Heart Attacks, Size Apparently Does Matter

Date:
March 9, 1999
Source:
Duke University Medical Center
Summary:
Just how do doctors figure out if a new drug for heart disease is effective? Most trials look at whether the drug reduces the number of deaths and heart attacks in group of patients taking it, compared to patients who don't. But what if the drug turns a large heart attack, one that could potentially kill the patient, into a smaller heart attack that does less damage?

NEW ORLEANS-- Just how do doctors figure out if a new drug for heart disease is effective? Most trials look at whether the drug reduces the number of deaths and heart attacks in group of patients taking it, compared to patients who don't.

But what if the drug turns a large heart attack, one that could potentially kill the patient, into a smaller heart attack that does less damage? Under the traditional way of testing medicines, the drug wouldn't be deemed effective, because it didn't reduce the number of heart attacks.

And that's far from an academic matter, say researchers at Duke University Medical Center, who argue that the way cardiology trials are conducted should be changed.

"Just counting the number of heart attacks may be the wrong way to measure a drug's effectiveness," says Dr. John Alexander, who prepared the results of his analysis for presentation Sunday at the annual scientific sessions of the American College of Cardiology.

"The fact that we may be able to reduce the size of myocardial infarction (MI) without necessarily reducing the incidence may be very important clinically," said Alexander, a cardiologist at the Duke Clinical Research Institute (DCRI).

Alexander based his findings on a close examination of data from the recently completed 10,948-patient PURSUIT trial of the drug eptifibatide (Integrilin), which was funded by the drug manufacturer, COR Therapeutics Inc., of San Francisco. He and his team found that while the drug slightly reduced the number of myocardial infarctions, it also reduced the size of MIs, possibly by converting larger ones into smaller ones.

Like many studies in heart disease, PURSUIT used the occurrence of an MI -- the death of heart muscle from the sudden loss of blood supply -- as a key part of the principal measurement of whether or not the patient benefited from the therapy. Since not all MIs are clear-cut, however, a committee of cardiologists not involved in the patient's care must determine whether or not an MI actually occurred, based on a review of enzyme levels, ECG tests and other clinical data.

After the trial was completed, the Duke researchers later went back and looked at the peak blood levels of an enzyme called creatine kinase-MB (CK-MB), which is released into the bloodstream by dying heart muscle cells. As more heart muscle dies, more CK-MB enters the bloodstream, making it a biochemical marker for the size of an MI.

They found that patients who received the drug eptifibatide tended to have smaller MIs, as measured by peak levels of CK-MB. More than 35 percent of patients who received eptifibatide had the lowest levels of CK-MB, compared to 29 percent for a placebo. At the highest levels of CK-MB in the blood, 38 percent received eptifibatide, 44 percent got the placebo. According to Alexander, several studies are in the planning stages at the DCRI incorporating the use of continuous endpoints that take into account MI size. The DCRI, which is made up of more than 700 cardiologists and other researchers, maintains the world's largest databank of cardiovascular disease. The fact that fewer people are dying from heart attacks during clinical trials places certain limitations on researchers, he said. For a study to have statistical significance using death as its only endpoint, more than 50,000 patients would need to be enrolled.

"Since this is not very practical, we have essentially been using MI as a surrogate for death," Alexander said. "This enables us to study the effects of drugs using a more manageable number of patients to achieve statistical significance."


Story Source:

The above story is based on materials provided by Duke University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Duke University Medical Center. "When It Comes To Heart Attacks, Size Apparently Does Matter." ScienceDaily. ScienceDaily, 9 March 1999. <www.sciencedaily.com/releases/1999/03/990309062812.htm>.
Duke University Medical Center. (1999, March 9). When It Comes To Heart Attacks, Size Apparently Does Matter. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/1999/03/990309062812.htm
Duke University Medical Center. "When It Comes To Heart Attacks, Size Apparently Does Matter." ScienceDaily. www.sciencedaily.com/releases/1999/03/990309062812.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Peace Corps Pulls Workers From W. Africa Over Ebola Fears

Peace Corps Pulls Workers From W. Africa Over Ebola Fears

Newsy (July 30, 2014) The Peace Corps is one of several U.S.-based organizations to pull workers out of West Africa because of the Ebola outbreak. Video provided by Newsy
Powered by NewsLook.com
Weather Kills 2K A Year, But Storms Aren't The Main Offender

Weather Kills 2K A Year, But Storms Aren't The Main Offender

Newsy (July 30, 2014) Health officials say 2,000 deaths occur each year in the U.S. due to weather, but it's excessive heat and cold that claim the most lives. Video provided by Newsy
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins